PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network

Background PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low‐density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high‐risk patients. We used real‐world electronic health record data to characterize use of PCSK9 inhibitor...

Full description

Bibliographic Details
Main Authors: Alanna M. Chamberlain, Yan Gong, Kathryn McAuliffe Shaw, Jiang Bian, Wen‐Liang Song, MacRae F. Linton, Vivian Fonseca, Eboni Price‐Haywood, Emily Guhl, Jordan B. King, Rashmee U. Shah, Jon Puro, Elizabeth Shenkman, Pamala A. Pawloski, Karen L. Margolis, Adrian F. Hernandez, Rhonda M. Cooper‐DeHoff
Format: Article
Language:English
Published: Wiley 2019-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
coronary artery disease
lipids
PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor
secondary prevention
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.118.011246

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.118.011246

Similar Items